Ionis Pharmaceuticals showcases strong Q1 2025 results with TRYNGOLZA's successful launch and raised revenue guidance.

Q1 2025 Earnings Conference Call April 30, 2025 11:30 AM ETCompany ParticipantsWade Walke - SVP, IRBrett Monia ...

The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's drug to treat a type of muscle-weakening ...

IMAAVY TM (nipocalimab-aahu) is a first-in-class FcRn (neonatal Fc receptor) inhibitor, designed to reduce the levels of ...

Neotonics brings together a thoughtful mix of probiotics and plant-based ingredients, each chosen for their unique role in ...

I have said — and my other family members have been super clear about this — that we disagree again and again and again on the things that he’s said.' ...

Health and Human Services employees were told in March to remove 'nicknames' from email systems and signatures to comply with ...